ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer

Cell Oncol (Dordr). 2023 Aug;46(4):1085-1095. doi: 10.1007/s13402-023-00799-5. Epub 2023 Mar 29.

Abstract

Background: Gemcitabine is the standard treatment for gallbladder cancer (GBC) patients, and the development of resistance frequently limits its efficacy. However, the molecular features and mechanisms of gemcitabine resistance (Gem-R) in GBC cells remain unknown. Herein, we aimed to explore the role of ELF3 in Gem-R of GBC, including the underlying mechanisms.

Methods: RNA sequencing was used to screen the essential genes related to the generation of Gem-R in GBC tissues. The correlation between Gem-R and ELF3 expression was identified in GDSC, GEO database, GBC tissues, and 3 GBC cell lines. Immunohistochemical staining, quantitative real-time polymerase chain reaction, and western blot were used to examine the expression of ELF3, PKMYT1, and CDK1. Luciferase reporter assays were used to identify the binding site of ELF3 in the PKMYT1 promoter region. CCK-8 assay and clonogenic survival assays were used to evaluate the sensitivity of gemcitabine in GBC cells. A GBC xenograft model was used to evaluate the influence of ELF3 on the therapeutic effect of gemcitabine.

Results: A consistently positive correlation between ELF3 expression and Gem-R, both in newly generated GBC RNA-seq data and in the datasets from GDSC and GEO. Gem-R in GBC cells was facilitated by ELF3 overexpression, whereas ELF3 knockdown had the opposite effect. In vivo experiments further proved that reducing ELF3 expression promoted the gemcitabine sensitivity of GBC cells and extended the survival time of mice that received orthotopic xenografted tumors. Mechanistically, ELF3 upregulated PKMYT1 expression by interacting with the DNA binding region of PKMYT1 in GBC cells, thereby promoting the phosphorylation of CDK1 and inducing Gem-R. Treatment with a combination of the PKMYT1 shRNA and gemcitabine significantly reduced the growth of GBC cells induced by overexpression of ELF3 in vitro and in vivo.

Conclusions: ELF3/PKMYT1/CDK1 axis significantly regulates Gem-R to GBC cells and may represent a promising drug target for treating GBC patients.

Keywords: CDK1; ELF3; Gallbladder cancer; Gemcitabine resistance; PKMYT1.

MeSH terms

  • Animals
  • Apoptosis
  • Cell Line, Tumor
  • Cell Proliferation
  • DNA-Binding Proteins / metabolism
  • Gallbladder Neoplasms* / drug therapy
  • Gallbladder Neoplasms* / genetics
  • Gemcitabine*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Membrane Proteins / metabolism
  • Mice
  • Protein-Tyrosine Kinases / genetics
  • Protein-Tyrosine Kinases / metabolism
  • Protein-Tyrosine Kinases / pharmacology
  • Proto-Oncogene Proteins c-ets / genetics
  • Proto-Oncogene Proteins c-ets / metabolism
  • Proto-Oncogene Proteins c-ets / pharmacology
  • RNA, Small Interfering / metabolism
  • Signal Transduction
  • Transcription Factors / metabolism

Substances

  • Gemcitabine
  • RNA, Small Interfering
  • ELF3 protein, human
  • DNA-Binding Proteins
  • Transcription Factors
  • Proto-Oncogene Proteins c-ets
  • PKMYT1 protein, human
  • Membrane Proteins
  • Protein-Tyrosine Kinases
  • CDK1 protein, human